Trial Profile
A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Apr 2019
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Ramipril
- Indications Diabetic nephropathies; Proteinuria; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DEER
- 03 Dec 2015 Planned End Date changed from 19 Jun 2016 to 1 Nov 2015 as reported by United Kingdom Clinical Research Network.
- 03 Dec 2015 Status changed from not yet recruiting to recruiting as reported by United Kingdom Clinical Research Network.
- 09 Aug 2014 Recruitment is expected to be completed by 1st November 2015 as reported by United Kingdom Clinical Research Network.